Feng-Cheng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Feng-Cheng Liu has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Tsang-Hsien Wu
The Ph.D. Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
2 shared publications - Ann Chen
Graduate Institute of Life Sciences National Defense Medical Center Taipei Taiwan
1 shared publication - Chih-Chien Sung
Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan
1 shared publication - Chih-Chin Kao
Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
1 shared publication Chih-Tsung Hung
Department of Dermatology, National Defense Medical University, Tri- Service General Hospital, Taipei, Taiwan
1 shared publication- Chun Austin Changou
Ph.D. Program for Translational Medicine, College of Medicine and Technology, Taipei Medical University, Taipei 110, Taiwan
1 shared publication
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Cost-effectiveness of virtual patient integration in dermatology education: evidence for precision education by learner expertise
Background: Educational technology adoption accelerates despite limited evidence of incremental value within already-effective curricula. Pragmatic evaluations examining cost-effectiveness and differential benefits across learner populations with varying expertise remain scarce. Objectives: To evaluate virtual patient integration into established flipped classroom curriculum, examining incremental educational outcomes, comprehensive cost-effectiveness, and systematic variation by training level. Methods: Sequential implementation study at a tertiary teaching hospital in Taiwan (2022–2025). Flipped classroom (FC; 2022–2023, N = 131) was followed by FC with virtual patients (FC + VP; 2024–2025, N = 161). Primary outcomes: knowledge acquisition (Cohen’s d , achievement rates ≥ 80%). Incremental cost-effectiveness ratios (ICERs) were calculated by training level. Results: Both approaches achieved extremely large learning effects (FC: d = 2.27; FC + VP: d = 2.43; >98% achievement; between-group differences non-significant). FC + VP required 3.08-fold higher per-student investment ($163 vs. $53). Cost-effectiveness varied dramatically: undergraduates showed meaningful gains (Δ d = + 0.29, ICER = $383/ d ), while postgraduates showed minimal benefit (Δ d = + 0.02, ICER = $4,670/ d )—a 12.2-fold difference. Germane cognitive load was associated with learning progress ( r = .196, R² = 8.5%); critical thinking was not independently associated ( p = .497). Conclusions: Near-universal competency is attainable through multiple instructional approaches. Virtual patient integration was associated with differential incremental value by learner expertise—meaningful for novices but negligible for advanced learners achieving comparable outcomes more efficiently. Findings support precision education frameworks targeting technology investments based on cost-effectiveness profiles rather than universal deployment.
- 6 July 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Open AccessCost-effectiveness of virtual patient integration in dermatology education: evidence for precision education by learner expertise
Background: Educational technology adoption accelerates despite limited evidence of incremental value within already-effective curricula. Pragmatic evaluations examining cost-effectiveness and differential benefits across learner populations with varying expertise remain scarce. Objectives: To evaluate virtual patient integration into established flipped classroom curriculum, examining incremental educational outcomes, comprehensive cost-effectiveness, and systematic variation by training level. Methods: Sequential implementation study at a tertiary teaching hospital in Taiwan (2022–2025). Flipped classroom (FC; 2022–2023, N = 131) was followed by FC with virtual patients (FC + VP; 2024–2025, N = 161). Primary outcomes: knowledge acquisition (Cohen’s d , achievement rates ≥ 80%). Incremental cost-effectiveness ratios (ICERs) were calculated by training level. Results: Both approaches achieved extremely large learning effects (FC: d = 2.27; FC + VP: d = 2.43; >98% achievement; between-group differences non-significant). FC + VP required 3.08-fold higher per-student investment ($163 vs. $53). Cost-effectiveness varied dramatically: undergraduates showed meaningful gains (Δ d = + 0.29, ICER = $383/ d ), while postgraduates showed minimal benefit (Δ d = + 0.02, ICER = $4,670/ d )—a 12.2-fold difference. Germane cognitive load was associated with learning progress ( r = .196, R² = 8.5%); critical thinking was not independently associated ( p = .497). Conclusions: Near-universal competency is attainable through multiple instructional approaches. Virtual patient integration was associated with differential incremental value by learner expertise—meaningful for novices but negligible for advanced learners achieving comparable outcomes more efficiently. Findings support precision education frameworks targeting technology investments based on cost-effectiveness profiles rather than universal deployment.
- Open Access
- 11 October 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 11, 100322
Novel variants in ARID1B, SPSB1, and RAET1-AS shape genetic susceptibility and protection in systemic lupus erythematosus and lupus nephritis
- 11 October 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 11, 100322
Open AccessNovel variants in ARID1B, SPSB1, and RAET1-AS shape genetic susceptibility and protection in systemic lupus erythematosus and lupus nephritis
- Open Access
- 10 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Identification of genetic variants associated with lupus nephritis in a Taiwanese cohort through systematic genetic screening
Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus (SLE), affecting about half of the patients. This research uses genotype–phenotype associations to identify genetic markers, enhancing our understanding of LN pathogenesis. This study used genotype–phenotype association to explore genetic variants linked to LN in a Taiwanese cohort from the Taiwan Precision Medicine Initiative (TPMI). Genotyping was performed on 244 SLE and 63 LN patients using the TPM array. Genomic DNA underwent quality control via the Axiom Analysis Suite. Chi-squared tests identified significant variants, which were annotated and assessed for functional impacts using the 1000 Genomes Project, gnomAD, enabling comprehensive genetic analysis. This study on a Taiwanese cohort (LN, SLE, LN/SLE) identified four significant genetic variants (p-values < 10−6) associated with LN: rs1025129 in HGF, rs80282109 in BACH2, rs516119 in SOX1, and rs134545 in TTC28. These variants may affect LN pathogenesis through splicing junction changes and gene expression regulation, highlighting their potential as biomarkers. Our research identified four novel variants (rs134545, rs516119, rs1025129, rs80282109) in LN patients through a genotype–phenotype study on a Taiwanese population, suggesting their roles in LN pathogenesis and supporting their potential as new disease biomarkers.
- 10 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessIdentification of genetic variants associated with lupus nephritis in a Taiwanese cohort through systematic genetic screening
Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus (SLE), affecting about half of the patients. This research uses genotype–phenotype associations to identify genetic markers, enhancing our understanding of LN pathogenesis. This study used genotype–phenotype association to explore genetic variants linked to LN in a Taiwanese cohort from the Taiwan Precision Medicine Initiative (TPMI). Genotyping was performed on 244 SLE and 63 LN patients using the TPM array. Genomic DNA underwent quality control via the Axiom Analysis Suite. Chi-squared tests identified significant variants, which were annotated and assessed for functional impacts using the 1000 Genomes Project, gnomAD, enabling comprehensive genetic analysis. This study on a Taiwanese cohort (LN, SLE, LN/SLE) identified four significant genetic variants (p-values < 10−6) associated with LN: rs1025129 in HGF, rs80282109 in BACH2, rs516119 in SOX1, and rs134545 in TTC28. These variants may affect LN pathogenesis through splicing junction changes and gene expression regulation, highlighting their potential as biomarkers. Our research identified four novel variants (rs134545, rs516119, rs1025129, rs80282109) in LN patients through a genotype–phenotype study on a Taiwanese population, suggesting their roles in LN pathogenesis and supporting their potential as new disease biomarkers.
- Open Access
NSC828779 Alleviates Renal Tubulointerstitial Lesions Involving Interleukin-36 Signaling in Mice
Renal tubulointerstitial lesions (TILs), a common pathologic hallmark of chronic kidney disease that evolves to end-stage renal disease, is characterized by progressive inflammation and pronounced fibrosis of the kidney. However, current therapeutic approaches to treat these lesions remain largely ineffectual. Previously, we demonstrated that elevated IL-36α levels in human renal tissue and urine are implicated in impaired renal function, and IL-36 signaling enhances activation of NLRP3 inflammasome in a mouse model of TILs. Recently, we synthesized NSC828779, a salicylanilide derivative (protected by U.S. patents with US 8975255 B2 and US 9162993 B2), which inhibits activation of NF-κB signaling with high immunomodulatory potency and low IC50, and we hypothesized that it would be a potential drug candidate for renal TILs. The current study validated the therapeutic effects of NSC828779 on TILs using a mouse model of unilateral ureteral obstruction (UUO) and relevant cell models, including renal tubular epithelial cells under mechanically induced constant pressure. Treatment with NSC828779 improved renal lesions, as demonstrated by dramatically reduced severity of renal inflammation and fibrosis and decreased urinary cytokine levels in UUO mice. This small molecule specifically inhibits the IL-36α/NLRP3 inflammasome pathway. Based on these results, the beneficial outcome represents synergistic suppression of both the IL-36α-activated MAPK/NLRP3 inflammasome and STAT3- and Smad2/3-dependent fibrogenic signaling. NSC828779 appears justified as a new drug candidate to treat renal progressive inflammation and fibrosis.
Open AccessNSC828779 Alleviates Renal Tubulointerstitial Lesions Involving Interleukin-36 Signaling in Mice
Renal tubulointerstitial lesions (TILs), a common pathologic hallmark of chronic kidney disease that evolves to end-stage renal disease, is characterized by progressive inflammation and pronounced fibrosis of the kidney. However, current therapeutic approaches to treat these lesions remain largely ineffectual. Previously, we demonstrated that elevated IL-36α levels in human renal tissue and urine are implicated in impaired renal function, and IL-36 signaling enhances activation of NLRP3 inflammasome in a mouse model of TILs. Recently, we synthesized NSC828779, a salicylanilide derivative (protected by U.S. patents with US 8975255 B2 and US 9162993 B2), which inhibits activation of NF-κB signaling with high immunomodulatory potency and low IC50, and we hypothesized that it would be a potential drug candidate for renal TILs. The current study validated the therapeutic effects of NSC828779 on TILs using a mouse model of unilateral ureteral obstruction (UUO) and relevant cell models, including renal tubular epithelial cells under mechanically induced constant pressure. Treatment with NSC828779 improved renal lesions, as demonstrated by dramatically reduced severity of renal inflammation and fibrosis and decreased urinary cytokine levels in UUO mice. This small molecule specifically inhibits the IL-36α/NLRP3 inflammasome pathway. Based on these results, the beneficial outcome represents synergistic suppression of both the IL-36α-activated MAPK/NLRP3 inflammasome and STAT3- and Smad2/3-dependent fibrogenic signaling. NSC828779 appears justified as a new drug candidate to treat renal progressive inflammation and fibrosis.
- Open Access
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
The property of drug-resistance may attenuate clinical therapy in cancer cells, such as chemoresistance to gefitinib in colon cancer cells. In previous studies, overexpression of PD-L1 causes proliferation and metastasis in cancer cells; therefore, the PD-L1 pathway allows tumor cells to exert an adaptive resistance mechanism in vivo. Nano-diamino-tetrac (NDAT) has been shown to enhance the anti-proliferative effect induced by first-line chemotherapy in various types of cancer, including colorectal cancer (CRC). In this work, we attempted to explore whether NDAT could enhance the anti-proliferative effect of gefitinib in CRC and clarified the mechanism of their interaction. The MTT assay was utilized to detect a reduction in cell proliferation in four primary culture tumor cells treated with gefitinib or NDAT. The gene expression of PD-L1 and other tumor growth-related molecules were quantified by quantitative polymerase chain reaction (qPCR). Furthermore, the identification of PI3K and PD-L1 in treated CRC cells were detected by western blotting analysis. PD-L1 presentation in HCT116 xenograft tumors was characterized by specialized immunohistochemistry (IHC) and the hematoxylin and eosin stain (H&E stain). The correlations between the change in PD-L1 expression and tumorigenic characteristics were also analyzed. (3) The PD-L1 was highly expressed in Colo_160224 rather than in the other three primary CRC cells and HCT-116 cells. Moreover, the PD-L1 expression was decreased by gefitinib (1 µM and 10 µM) in two cells (Colo_150624 and 160426), but 10 µM gefitinib stimulated PD-L1 expression in gefitinib-resistant primary CRC Colo_160224 cells. Inactivated PI3K reduced PD-L1 expression and proliferation in CRC Colo_160224 cells. Gefitinib didn’t inhibit PD-L1 expression and PI3K activation in gefitinib-resistant Colo_160224 cells. However, NDAT inhibited PI3K activation as well as PD-L1 accumulation in gefitinib-resistant Colo_160224 cells. The combined treatment of NDAT and gefitinib inhibited pPI3K and PD-L1 expression and cell proliferation. Additionally, NDAT reduced PD-L1 accumulation and tumor growth in the HCT116 (K-RAS mutant) xenograft experiment. (4) Gefitinib might suppress PD-L1 expression but did not inhibit proliferation through PI3K in gefitinib-resistant primary CRC cells. However, NDAT not only down-regulated PD-L1 expression via blocking PI3K activation but also inhibited cell proliferation in gefitinib-resistant CRCs.
Open AccessNDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
The property of drug-resistance may attenuate clinical therapy in cancer cells, such as chemoresistance to gefitinib in colon cancer cells. In previous studies, overexpression of PD-L1 causes proliferation and metastasis in cancer cells; therefore, the PD-L1 pathway allows tumor cells to exert an adaptive resistance mechanism in vivo. Nano-diamino-tetrac (NDAT) has been shown to enhance the anti-proliferative effect induced by first-line chemotherapy in various types of cancer, including colorectal cancer (CRC). In this work, we attempted to explore whether NDAT could enhance the anti-proliferative effect of gefitinib in CRC and clarified the mechanism of their interaction. The MTT assay was utilized to detect a reduction in cell proliferation in four primary culture tumor cells treated with gefitinib or NDAT. The gene expression of PD-L1 and other tumor growth-related molecules were quantified by quantitative polymerase chain reaction (qPCR). Furthermore, the identification of PI3K and PD-L1 in treated CRC cells were detected by western blotting analysis. PD-L1 presentation in HCT116 xenograft tumors was characterized by specialized immunohistochemistry (IHC) and the hematoxylin and eosin stain (H&E stain). The correlations between the change in PD-L1 expression and tumorigenic characteristics were also analyzed. (3) The PD-L1 was highly expressed in Colo_160224 rather than in the other three primary CRC cells and HCT-116 cells. Moreover, the PD-L1 expression was decreased by gefitinib (1 µM and 10 µM) in two cells (Colo_150624 and 160426), but 10 µM gefitinib stimulated PD-L1 expression in gefitinib-resistant primary CRC Colo_160224 cells. Inactivated PI3K reduced PD-L1 expression and proliferation in CRC Colo_160224 cells. Gefitinib didn’t inhibit PD-L1 expression and PI3K activation in gefitinib-resistant Colo_160224 cells. However, NDAT inhibited PI3K activation as well as PD-L1 accumulation in gefitinib-resistant Colo_160224 cells. The combined treatment of NDAT and gefitinib inhibited pPI3K and PD-L1 expression and cell proliferation. Additionally, NDAT reduced PD-L1 accumulation and tumor growth in the HCT116 (K-RAS mutant) xenograft experiment. (4) Gefitinib might suppress PD-L1 expression but did not inhibit proliferation through PI3K in gefitinib-resistant primary CRC cells. However, NDAT not only down-regulated PD-L1 expression via blocking PI3K activation but also inhibited cell proliferation in gefitinib-resistant CRCs.